Silexion Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2013	FY 2012
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Net Income	-16.44	-4.94	-1.36	-0.94
Depreciation & Amortization	0.03	0.05	0	0
Loss (Gain) From Sale of Assets	0.02	-0	-	-
Stock-Based Compensation	5.86	0.13	0.42	0.04
Other Operating Activities	3.72	0.15	-	-
Change in Accounts Receivable	-	-	0.06	-0.1
Change in Accounts Payable	0.61	0.08	0.02	0.06
Change in Other Net Operating Assets	-2.19	0.01	0.05	0.03
Operating Cash Flow	-8.4	-4.53	-0.79	-0.91
Capital Expenditures	-0.02	-0.01	-0.01	-0
Sale of Property, Plant & Equipment	-	0.08	-	-
Investment in Securities	-	0.51	-	-
Other Investing Activities	-	-	-0.01	-0.03
Investing Cash Flow	-0.02	0.57	-0.02	-0.03
Long-Term Debt Repaid	-0.25	-	-	-
Net Debt Issued (Repaid)	-0.25	-	-	-
Issuance of Common Stock	3.05	-	-	1.72
Other Financing Activities	2.3	-	-	-
Financing Cash Flow	5.1	0.52	-	1.72
Foreign Exchange Rate Adjustments	-0.06	-0.23	-	-
Net Cash Flow	-3.38	-3.66	-0.81	0.78
Free Cash Flow	-8.42	-4.54	-0.8	-0.91
Free Cash Flow Per Share	-13.49	-40.64	-48.23	-64.06
Cash Interest Paid	0.03	-	-	-
Levered Free Cash Flow	-2.41	-	-0.31	-
Unlevered Free Cash Flow	-2.39	-	-0.3	-
Change in Net Working Capital	0.4	-	-0.12	-

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q